E2F-1 overexpression in cardiomyocytes induces downregulation of p21(CIP1) and p27(KIP1) and release of active cyclin-dependent kinases in the presence of insulin-like growth factor I

Circulation Research

Volumn 85, Issue 2, 1999, Pages 128-136

  Von Harsdorf, Rüdiger ^a   Hauck, Ludger ^a   Mehrhof, Felix ^a   Wegenka, Ursula ^a   Cardoso, M Cristina ^b   Dietz, Rainer ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Apoptosis; Cardiomyocyte; Cell cycle; E2F 1; Insulin like growth factor I

Indexed keywords

ANNEXIN; CYCLIN DEPENDENT KINASE; DNA; PROTEIN P16; PROTEIN P21; PROTEIN P27; SOMATOMEDIN C; TRANSCRIPTION FACTOR E2F;

ADENOVIRUS; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE S PHASE; CELL REGENERATION; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME RELEASE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HEART MUSCLE CELL; HEART MUSCLE INJURY; IMMUNOFLUORESCENCE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

EID: 0033597954     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.85.2.128     Document Type: Article

References (46)

1. Goldstein MA, Claycomb WC, Schwanz A. DNA synthesis and mitosis in well-differentiated mammalian cardiocytes. Science. 1974;183: 212-213.
2. Agah R, Kirshenbaum LA, Abdellatif M, Truong LD, Chakraborty S, Michael LH, Schneider MD. Adenoviral delivery of E2F-1 directs cell cycle reentry and p53-independent apoptosis in postmitotic adult myocardium In vivo. J Clin Invest. 1997;100:2722-2728.
3. Kirshenbaum LA, Schneider MD. Adenovirus E1A represses cardiac gene transcription and reactivates DNA synthesis in ventricular myocytes, via alternative pocket protein-and p300-binding domains. J Biol Chem. 1995;270:7791-7794.
4. Kirshenbaum LA, Abdellatif M, Chakraborty S, Schneider MD. Human E2F-1 reactivates cell cycle progression in ventricular myocytes and represses cardiac gene transcription. Dev Biol. 1996;179:402-411.
5. Liu Y, Kitsis RN. Induction of DNA synthesis and apoptosis in cardiac myocytes by E1A oncoprotein. J Cell Biol. 1996;133:325-334.
6. Sen A, Dunnmon P, Henderson SA, Gerard RD, Chien KR. Terminally differentiated neonatal rat myocardial cells proliferate and maintain specific differentiated functions following expression of SV40 large T antigen. J Biol Chem. 1988;263:19132-19136.
7. Soonpaa MH, Koh GY, Pajak L, Jing S, Wang H, Franklin MT, Kim KK, Field LJ. Cyclin D1 overexpression promotes cardiomyocyte DNA synthesis and multinucleation in transgenic mice. J Clin Invest. 1997;99: 2644-2654.
8. Field LJ. Atrial natriuretic factor-SV40 T antigen transgenes produce tumors and cardiac arrhythmias in mice. Science. 1988;239:1029-1033.
9. Pines J. Cyclins, CDKs, and cancer. Semin Cancer Biol. 1995;6:63-72.
10. Morgan DO. Principles of CDK regulation. Nature. 1995;374:131-134.
11. Harper JW. Cyclin dependent kinase inhibitors. Cancer Surv. 1997;29: 91-107.
12. Yoshizumi M, Lee WS, Hsieh CM, Tsai JC, Li J, Perrella MA, Patterson C, Endege WO, Schlegel R, Lee ME. Disappearance of cyclin A correlates with permanent withdrawal of cardiomyocytes from the cell cycle in human and rat hearts. J Clin Invest. 1995;95:2275-2280.
13. Brooks G, Poolman RA, McGill CJ, Li JM. Expression and activities of cyclins and cyclin-dependent kinases in developing rat ventricular myocytes. J Mol Cell Cardiol. 1997;29:2261-2271.
14. Kang MJ, Koh GY. Differential and dramatic changes of cyclin-dependent kinase activities in cardiomyocytes during the neonatal period. J Mol Cell Cardiol. 1997;29:1767-1777.
15. cdc2 gene by cdc2 promoter binding factor/nuclear factor-Y in fetal rat ventricular myocytes. Circ Res. 1998;82:251-260.
16. Flink IL, Oana S, Maitra N, Bahl JJ, Morkin E. Changes in E2F complexes containing retinoblastoma protein family members and increased cyclin-dependent kinase inhibitor activities during terminal differentiation of cardiomyocytes. J Mol Cell Cardiol. 1998;30:563-578.
17. KIP1, in rat hearts during development. J Mol Cell Cardiol. 1998;30:463-474.
18. Simpson P, McGrath A, Savion S. Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum an by catecholamines. Circ Res. 1982;51:787-801.
19. Gomez Foix AM, Coats WS, Baque S, Alam T, Gerard RD, Newgard CB. Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepalocytes confers altered regulation of glycogen metabolism. J Biol Chem. 1992;267:25129-25134.
20. DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR. Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci U S A. 1997;94:7245-7250.
21. Toyoshima H, Hunter T. p27, A novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 1994;78:67-74.
22. Wang J, Walsh K. Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science. 1996;273:359-361.
23. Osterziel KJ, Strohm O, Schuler J, Friedrich M, Hanlein D. Willenbrock R. Anker SD, Poole-Wilson PA, Ranke MB, Dietz R. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet. 1998;351:1233-1237.
24. Kajstura J, Cheng W. Reiss K, Anversa P. The IGF-1-IGF-1 receptor system modulates myocyte proliferation but not myocyte cellular hypertrophy in vitro. Exp Cell Res. 1994;215:273-283.
25. Reiss K, Cheng W, Ferber A, Kajstura J, Li P, Li B, Olivetti G, Homcy CJ, Baserga R, Anversa P. Overexpression of insulin-like growth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice. Proc Natl Acad Sci U S A. 1996;93:8630-8635.
26. Ito H, Hiroe M, Hirata Y, Tsujino M. Adachi S, Shichiri M, Koike A, Nogami A, Marumo F. Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation. 1993;87:1715-1721.
27. Liu Q, Yan H, Dawes NJ, Mottino GA, Frank JS, Zhu H. Insulin-like growth factor II induces DNA synthesis in fetal ventricular myocytes in vitro. Circ Res. 1996;79:716-726.
28. Thorbum A, Thorbum J, Chen SY, Powers S, Shubeita HE, Feramisco JR, Chien KR. HRas-dependent pathways can activate morphological and genetic markers of cardiac muscle cell hypertrophy [published erratum appears in J Biol Chem. 1993;268:16082]. J Biol Chem. 1993;268: 2244-2249.
29. Sadoshima J, Aoki H, Izumo S. Angiotensin II and serum differentially regulate expression of cyclins, activity of cyclin-dependent kinases, and phosphorylation of retinoblastoma gene product in neonatal cardiac myocytes. Circ Res. 1997;80:228-241.
30. Parrizas M, Saltiel AR, LeRoith D. Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways. J Biol Chem. 1997;272:154-161.
31. Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol. 1997;17:1595-1606.
32. Kulik G, Weber MJ. Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I. Mol Cell Biol. 1998; 18:6711-6718.
33. Wang L, Ma W, Markovich R, Chen JW, Wang PH. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res. 1998;83:516-522.
34. Zak R. Development and proliferative capacity of cardiac muscle cells. Circ Res. 1974;35(suppl II):17-26.
35. Soonpaa MH, Kim KK, Pajak L, Franklin M. Field LJ. Cardiomyocyte DNA synthesis and binucleation during murine development. Am J Physiol. 1996;271:H2183-H2189.
36. Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin WG Jr. Livingston DM, Orkin SH, Greenberg ME. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell. 1996;85:549-561.
37. Holmberg C. Helin K, Sehested M, Karlstrom O. E2F-1-induced p53-independent apoptosis in transgenic mice. Oncogene. 1998;17:143-155.
38. Harrington EA, Bennett MR, Fanidi A, Evan GI. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J. 1994;13: 3286-3295.
39. Kaplan MH, Daniel C, Schindler U, Grusby MJ. Stat proteins control lymphocyte proliferation by regulating p27Kip1 expression. Mol Cell Biol. 1998;18:1996-2003.
40. Firpo EJ, Koff A, Solomon MJ, Roberts JM. Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes. Mol Cell Biol. 1994;14:4889-4901.
41. Winston J, Dong F, Pledger WJ. Differential modulation of G1 cyclins and the Cdk inhibitor p27 kip1 by platelet-derived growth factor and plasma factors in density-arrested fibroblasts. J Biol Chem. 1996;271: 11253-11260.
42. Mann DJ, Higgins T, Jones NC, Rozengurt E. Differential control of cyclins D1 and D3 and the cdk inhibitor p27Kip1 by diverse signalling pathways in Swiss 3T3 cells. Oncogene. 1997;14:1759-1766.
43. Leone G, DeGregori J, Sears R, Jakoi L, Nevins JR. Myc, and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature. 1997;387:422-426.
44. Reynisdottir I, Massague J. The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev. 1997;11:492-503.
45. Coats S, Flanagan WM, Nourse J, Roberts JM. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science. 1996; 272:877-880.
46. Mal A, Poon RY, Howe PH, Toyoshima H, Hunter T, Harter ML. Inactivation of p27Kip1 by the viral E1A oncoprotein in TGFβ-treated cells. Nature. 1996;380:262-265.